Goldman Sachs upgraded Galapagos NV (NASDAQ:GLPG) from Neutral to Buy in a report released today.
- Updated: October 18, 2016
Displaying a price of $63.51, Galapagos NV (NASDAQ:GLPG) traded 5.80% higher on the day. With the last close up 23.95% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. Galapagos NV has recorded a 50-day average of $61.70 and a two hundred day average of $54.21. Volume of trade was up over the average, with 306,919 shares of GLPG changing hands over the typical 86,583
Goldman Sachs has upgraded Galapagos NV (NASDAQ:GLPG) from Neutral to Buy in a statement released on 10/18/2016.
On Monday October 10, 2016, Zacks Investment Research released a statement for Galapagos NV (NASDAQ:GLPG) bumped up the target price from $0.00 to $74.00 that suggested an upside of 0.13%.
With a total market value of $0, Galapagos NV has with a one year low of $37.03 and a one year high of $73.37 .
A total of 1 firm has issued a research note on the company. zero equity analysts rating the company a strong buy, two equity analysts rating the company a buy, zero equity analysts rating the company a hold, zero firms rating the stock a underperform, and finally 0 firms rating the stock a sell with a consensus target price of $92.78.
About Galapagos NV (NASDAQ:GLPG)
Galapagos NV is a Belgium-based biotechnology company. The Company's activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates. As of December 31, 2011, Galapagos NV was, through its subsidiaries, active in Belgium, France, Switzerland, the Netherlands, the United Kingdom, Germany, the United States and Croatia. In April 2014, it sold BioFocus and Argenta service division operations to Charles River Laboratories International.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.